29 junio 2015
The enzyme PI3K appears to be exploited in almost every type of human cancer, making it the focus of considerable interest as a therapeutic target. However, PI3K inhibitors have only shown modest clinical activity. Now, new research shows that treatment with PI3K inhibitors alone may actually make a patient’s cancer even worse by promoting more aggressive tumor cell behavior and increasing the cancer’s potential of spreading to other organs.
http://feeds.sciencedaily.com/~r/sciencedaily/~3/kTD28SO7KcY/150629152709.htm
